Abstract
We investigated the dermal inflammatory infiltrate and the expression of HLA-DR and beta 2-microglobulin on the tumour cells in 8 Bowen's disease (BD) using a series of monoclonal antibodies. The inflammatory infiltrate was classified as mild, moderate or heavy. The infiltrate in all cases consisted mainly of T cells (55 +/- 21%) and where the T helper (TH) subset predominated over the T suppressor/cytotoxic (TS/C) subset (TH/TS/C ratio of 2.4 +/- 1.0). The mean percentage of HLA-DR positive cells was 58 +/- 18%, Langerhans cells (LC) 4 +/- 1% and Leu-M5 positive cells (monocytes/macrophages) 9 +/- 2%. The mean percentage of B cells and natural killer (NK) cells was 4 +/- 5% and 1 +/- 2% respectively. B cells and NK cells did not invade any of the tumours. In the 5 BD with moderate or heavy infiltrate, TH cells, TS/C cells and Leu-M5 positive cells did invade the tumour. In the tumour area where there was invasion, the number of LC was increased and HLA-DR was expressed on the cells. beta 2-microglobulin was generally expressed on the tumour cells of BD. We concluded that there is evidence for a T cell-mediated anti-tumour immune response which may account for the infrequent invasive growth in BD.
References
Mar 1, 1979·Journal of the National Cancer Institute·R B Herberman, H T Holden
Jan 1, 1989·Journal of the American Academy of Dermatology·J M HabetsT van Joost
Apr 1, 1987·Journal of the American Academy of Dermatology·A KohchiyamaH Ueki
Oct 1, 1986·The Journal of Investigative Dermatology·A KohchiyamaH Ueki
Jan 1, 1987·Virchows Archiv. A, Pathological Anatomy and Histopathology·E RalfkiaerD Y Mason
Mar 1, 1988·The Journal of Investigative Dermatology·J M HabetsT van Joost
Dec 1, 1985·International Journal of Dermatology·L A HuaR W Goltz
May 1, 1981·The British Journal of Dermatology·M L Turbitt, R M Mackie
Nov 1, 1982·The Journal of Dermatologic Surgery and Oncology·N F EaglsteinJ E Allen
Feb 1, 1983·European Journal of Cancer & Clinical Oncology·A S Daar, J W Fabre
Mar 1, 1984·The Journal of Investigative Dermatology·E B BröckerC Sorg
Oct 1, 1983·The British Journal of Dermatology·G MauduitR M MacKie
Oct 2, 1981·Science·R B Herberman, J R Ortaldo
May 1, 1985·Immunology Today·A Mantovani, R Evans
Citations
Nov 7, 2000·Journal of Surgical Oncology·P G Jackson, S R Evans
Aug 1, 1996·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·A Iamaroon, R A Vickers
Dec 18, 2004·The Journal of Foot and Ankle Surgery : Official Publication of the American College of Foot and Ankle Surgeons·George T LiuJohn S Steinberg
Jan 1, 1994·The Journal of Dermatology·J NakayamaN Kinoshita
Jul 1, 1992·The Journal of Dermatology·H TeraoY Hori
Mar 1, 1992·The Journal of Dermatology·D C MoonY Hori
Dec 18, 2013·PloS One·Kurt ReifenbergMichael Torzewski
Feb 24, 2001·Journal of the American Academy of Dermatology·A Mackenzie-WoodM L Owens
Feb 1, 1990·European Journal of Immunology·R ReuterR Lührmann
May 23, 2006·Journal of the American Academy of Dermatology·Girish K PatelRichard J Motley
Mar 21, 1998·European Journal of Clinical Investigation·C Cocito, H Maes